JP7603918B2 - プログラム可能なポリマー薬 - Google Patents

プログラム可能なポリマー薬 Download PDF

Info

Publication number
JP7603918B2
JP7603918B2 JP2021559817A JP2021559817A JP7603918B2 JP 7603918 B2 JP7603918 B2 JP 7603918B2 JP 2021559817 A JP2021559817 A JP 2021559817A JP 2021559817 A JP2021559817 A JP 2021559817A JP 7603918 B2 JP7603918 B2 JP 7603918B2
Authority
JP
Japan
Prior art keywords
occurrence
compound
independently
compounds
moiety
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021559817A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022526014A (ja
JP2022526014A5 (enExample
Inventor
トレイシー マトライ
シャラット シン
シー フレデリック バットレル
マイケル ヴァンブラント
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sony Corp
Sony Group Corp
Original Assignee
Sony Corp
Sony Group Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sony Corp, Sony Group Corp filed Critical Sony Corp
Publication of JP2022526014A publication Critical patent/JP2022526014A/ja
Publication of JP2022526014A5 publication Critical patent/JP2022526014A5/ja
Priority to JP2024216317A priority Critical patent/JP7903604B2/ja
Application granted granted Critical
Publication of JP7603918B2 publication Critical patent/JP7603918B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/605—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the macromolecule containing phosphorus in the main chain, e.g. poly-phosphazene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6883—Polymer-drug antibody conjugates, e.g. mitomycin-dextran-Ab; DNA-polylysine-antibody complex or conjugate used for therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0041—Xanthene dyes, used in vivo, e.g. administered to a mice, e.g. rhodamines, rose Bengal
    • A61K49/0043—Fluorescein, used in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0054—Macromolecular compounds, i.e. oligomers, polymers, dendrimers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0058—Antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/22—Amides of acids of phosphorus
    • C07F9/24—Esteramides
    • C07F9/2404—Esteramides the ester moiety containing a substituent or a structure which is considered as characteristic
    • C07F9/2408—Esteramides the ester moiety containing a substituent or a structure which is considered as characteristic of hydroxyalkyl compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/572—Five-membered rings
    • C07F9/5728—Five-membered rings condensed with carbocyclic rings or carbocyclic ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/576—Six-membered rings
    • C07F9/58—Pyridine rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65586—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system at least one of the hetero rings does not contain nitrogen as ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
    • C07K5/06052—Val-amino acid

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2021559817A 2019-04-11 2020-04-10 プログラム可能なポリマー薬 Active JP7603918B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024216317A JP7903604B2 (ja) 2019-04-11 2024-12-11 プログラム可能なポリマー薬

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962832723P 2019-04-11 2019-04-11
US62/832,723 2019-04-11
US201962877144P 2019-07-22 2019-07-22
US62/877,144 2019-07-22
PCT/US2020/027750 WO2020210689A1 (en) 2019-04-11 2020-04-10 Programmable polymeric drugs

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024216317A Division JP7903604B2 (ja) 2019-04-11 2024-12-11 プログラム可能なポリマー薬

Publications (3)

Publication Number Publication Date
JP2022526014A JP2022526014A (ja) 2022-05-20
JP2022526014A5 JP2022526014A5 (enExample) 2024-07-11
JP7603918B2 true JP7603918B2 (ja) 2024-12-23

Family

ID=70476549

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021559817A Active JP7603918B2 (ja) 2019-04-11 2020-04-10 プログラム可能なポリマー薬
JP2024216317A Active JP7903604B2 (ja) 2019-04-11 2024-12-11 プログラム可能なポリマー薬

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024216317A Active JP7903604B2 (ja) 2019-04-11 2024-12-11 プログラム可能なポリマー薬

Country Status (6)

Country Link
US (1) US20220160887A1 (enExample)
EP (1) EP3952916A1 (enExample)
JP (2) JP7603918B2 (enExample)
KR (1) KR20210152523A (enExample)
CN (1) CN114430738A (enExample)
WO (1) WO2020210689A1 (enExample)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3019559A4 (en) 2013-08-22 2017-04-05 Sony Corporation Water soluble fluorescent or colored dyes and methods for their use
WO2016138461A1 (en) 2015-02-26 2016-09-01 Sony Corporation Water soluble fluorescent or colored dyes comprising conjugating groups
KR102646956B1 (ko) 2015-02-26 2024-03-14 소니그룹주식회사 페닐에티닐나프탈렌 염료 및 이의 사용 방법
KR102765335B1 (ko) 2015-05-11 2025-02-13 소니그룹주식회사 초휘도 이량체성 또는 중합체성 염료
EP3436528B1 (en) 2016-04-01 2025-07-02 Sony Group Corporation Ultra bright dimeric or polymeric dyes with rigid spacing groups
BR112018070164B1 (pt) 2016-04-01 2022-09-27 Sony Corporation Of America Corantes diméricos ou poliméricos ultrabrilhantes
CN109153860B (zh) 2016-04-06 2021-04-23 索尼公司 具有间隔连接体基团的超高亮二聚体或聚合物染料
WO2017189805A1 (en) 2016-04-27 2017-11-02 Abbvie Inc. Methods of treatment of diseases in which il-13 activity is detrimental using anti-il-13 antibodies
BR112018073199A2 (pt) 2016-05-11 2019-04-16 Sony Corporation corantes diméricos ou poliméricos ultrabrilhantes
WO2018022925A1 (en) 2016-07-29 2018-02-01 Sony Corporation Ultra bright dimeric or polymeric dyes and methods for preparation of the same
KR20260011205A (ko) 2017-10-05 2026-01-22 소니그룹주식회사 프로그램가능한 중합체성 약물
CN111836645A (zh) 2017-11-16 2020-10-27 索尼公司 可编程的聚合药物
WO2019140128A1 (en) 2018-01-12 2019-07-18 Sony Corporation Phosphoalkyl polymers comprising biologically active compounds
EP3737417B1 (en) 2018-01-12 2025-08-27 Sony Group Corporation Phosphoalkyl ribose polymers comprising biologically active compounds
US12076407B2 (en) 2018-01-12 2024-09-03 Sony Group Corporation Polymers with rigid spacing groups comprising biologically active compounds
EP3769085B1 (en) 2018-03-19 2022-08-24 Sony Group Corporation Use of divalent metals for enhancement of fluorescent signals
KR102864292B1 (ko) 2018-03-21 2025-09-26 소니그룹주식회사 링커 군을 갖는 중합체성 텐덤 염료
JP7580689B2 (ja) 2018-06-27 2024-11-12 ソニーグループ株式会社 デオキシリボースを含むリンカー基を有するポリマー色素
US12578342B2 (en) 2018-07-13 2026-03-17 Sony Group Corporation Polymeric dyes having a backbone comprising organophosphate units
EP3861074A2 (en) 2019-09-26 2021-08-11 Sony Group Corporation Polymeric tandem dyes with linker groups
EP4038081A1 (en) 2019-09-30 2022-08-10 Sony Group Corporation Nucleotide probes
KR20230092863A (ko) 2020-06-11 2023-06-26 프로벤션 바이오, 인코포레이티드 제1형 당뇨병을 예방하기 위한 방법 및 조성물
EP4256078A1 (en) 2020-12-07 2023-10-11 Sony Group Corporation Spacing linker group design for brightness enhancement in dimeric or polymeric dyes
MX2023013851A (es) 2021-05-24 2023-12-08 Provention Bio Inc Metodos para el tratamiento de diabetes tipo 1.
US20240350645A1 (en) * 2021-07-22 2024-10-24 Sony Group Corporation Automated synthesis of polymeric drugs
CN117750977A (zh) * 2021-07-22 2024-03-22 索尼集团公司 聚合型药物的自动合成
EP4590340A1 (en) * 2022-09-22 2025-07-30 Sony Group Corporation Polymers with steroids or vitamins
CN120077057A (zh) 2022-10-04 2025-05-30 伊莱利利公司 Trem2相关疾病和病症的基因治疗
AR131035A1 (es) 2022-11-11 2025-02-12 Lilly Co Eli Ácidos nucleicos sintéticos que incluyen constructos promotores dirigidos a astrocitos y métodos de uso de los mismos
WO2026043765A1 (en) 2024-08-21 2026-02-26 Eli Lilly And Company Engineered regulatory splice elements for gene therapies

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016183185A1 (en) 2015-05-11 2016-11-17 Sony Corporation Ultra bright dimeric or polymeric dyes
WO2017197144A1 (en) 2016-05-11 2017-11-16 Sony Corporation Ultra bright dimeric or polymeric dyes
WO2019071208A1 (en) 2017-10-05 2019-04-11 Sony Corporation PROGRAMMABLE POLYMERIC MEDICAMENTS

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9545447B2 (en) * 2013-01-04 2017-01-17 The Texas A&M University System Polymer-drug systems
EP3019559A4 (en) * 2013-08-22 2017-04-05 Sony Corporation Water soluble fluorescent or colored dyes and methods for their use
WO2016138461A1 (en) 2015-02-26 2016-09-01 Sony Corporation Water soluble fluorescent or colored dyes comprising conjugating groups
JP6817288B2 (ja) * 2015-08-10 2021-01-20 ハンジョウ ディーエーシー バイオテック シーオー．，エルティディ．Ｈａｎｇｚｈｏｕ Ｄａｃ Ｂｉｏｔｅｃｈ Ｃｏ．，Ｌｔｄ． 新規な連結体及び生体分子と薬物との特異的共役におけるその使用
EP3436528B1 (en) * 2016-04-01 2025-07-02 Sony Group Corporation Ultra bright dimeric or polymeric dyes with rigid spacing groups
BR112018070164B1 (pt) * 2016-04-01 2022-09-27 Sony Corporation Of America Corantes diméricos ou poliméricos ultrabrilhantes
CN109153860B (zh) * 2016-04-06 2021-04-23 索尼公司 具有间隔连接体基团的超高亮二聚体或聚合物染料
US11390754B2 (en) * 2016-05-10 2022-07-19 Sony Corporation Compositions comprising a polymeric dye and a cyclodextrin and uses thereof
WO2018022925A1 (en) * 2016-07-29 2018-02-01 Sony Corporation Ultra bright dimeric or polymeric dyes and methods for preparation of the same
US12290571B2 (en) * 2017-10-05 2025-05-06 Sony Group Corporation Programmable dendritic drugs
CN111836645A (zh) * 2017-11-16 2020-10-27 索尼公司 可编程的聚合药物
EP3737417B1 (en) * 2018-01-12 2025-08-27 Sony Group Corporation Phosphoalkyl ribose polymers comprising biologically active compounds
US12076407B2 (en) * 2018-01-12 2024-09-03 Sony Group Corporation Polymers with rigid spacing groups comprising biologically active compounds
EP3769085B1 (en) * 2018-03-19 2022-08-24 Sony Group Corporation Use of divalent metals for enhancement of fluorescent signals
KR102864292B1 (ko) * 2018-03-21 2025-09-26 소니그룹주식회사 링커 군을 갖는 중합체성 텐덤 염료
JP7580689B2 (ja) * 2018-06-27 2024-11-12 ソニーグループ株式会社 デオキシリボースを含むリンカー基を有するポリマー色素
EP3861074A2 (en) * 2019-09-26 2021-08-11 Sony Group Corporation Polymeric tandem dyes with linker groups

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016183185A1 (en) 2015-05-11 2016-11-17 Sony Corporation Ultra bright dimeric or polymeric dyes
WO2017197144A1 (en) 2016-05-11 2017-11-16 Sony Corporation Ultra bright dimeric or polymeric dyes
WO2019071208A1 (en) 2017-10-05 2019-04-11 Sony Corporation PROGRAMMABLE POLYMERIC MEDICAMENTS

Also Published As

Publication number Publication date
JP2025039569A (ja) 2025-03-21
JP2022526014A (ja) 2022-05-20
US20220160887A1 (en) 2022-05-26
JP7903604B2 (ja) 2026-08-12
KR20210152523A (ko) 2021-12-15
CN114430738A (zh) 2022-05-03
EP3952916A1 (en) 2022-02-16
WO2020210689A1 (en) 2020-10-15

Similar Documents

Publication Publication Date Title
JP7551060B2 (ja) プログラム可能なポリマー薬
JP7618137B2 (ja) プログラム可能なポリマー薬
JP2025039569A (ja) プログラム可能なポリマー薬
JP7515785B2 (ja) 生物学的に活性な化合物を含むホスホアルキルポリマー
US20260108619A1 (en) Conjugation linkers, cell binding molecule-drug conjugates containing the linkers, methods of making and uses such conjugates with the linkers
JP7813098B2 (ja) 生物学的に活性な化合物を含む剛性間隔基を有するポリマー
JP7551056B2 (ja) プログラマブルなポリマー薬物
JP2024050717A (ja) 生物学的に活性な化合物を含むイオン性ポリマー
US10328157B2 (en) Acetylenedicarboxyl linkers and their uses in specific conjugation of a cell-binding molecule
CA2991384C (en) Bridge linkers for conjugation of a cell-binding molecule
JP2024040167A (ja) 生物学的に活性な化合物を含むホスホアルキルリボースポリマー
JP6332773B2 (ja) 薬物と細胞結合分子との共役のための新規細胞毒性分子
JP6133431B2 (ja) 親水性連結体及び薬物分子と細胞結合分子との共役反応における親水性連結体の使用
JP2020536845A (ja) プログラマブルな樹枝状薬物
JP2025188196A (ja) コンジュゲート分子
SG10202112977YA (en) Bridge linkers for conjugation of cell-binding molecules

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230410

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230410

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240304

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240502

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20240703

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240805

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240924

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20241111

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20241124

R150 Certificate of patent or registration of utility model

Ref document number: 7603918

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150